Fatal events during clinical trials: an evaluation of deaths during breast cancer studies
Jenny Furlanetto, Gunter Von Minckwitz, Bianca Lederer, Volker Möbus, Andreas Schneeweiss, Jens Huober, Peter A Fasching, Bernd Gerber, Ingo Bauerfeind, Ulrike Nitz, Hans-Joachim Lück, Claus Hanusch, Christoph Thomssen, Michael Untch, Valentina Nekljudova, Keyur Mehta & Sibylle Loibl
Death during study treatment was mainly related to infections, and patients with advanced disease, high BMI, underlying comorbidities, CRFs and concomitant medications. If considered for study participation these patients need careful monitoring due to their higher risk for death on study.
|citation||Furlanetto J, von Minckwitz G, Lederer B, Möbus V, Schneeweiss A, Huober J, Fasching P A, Gerber B, Bauerfeind I, Nitz U, Lück H J, Hanusch C, Thomssen C, Untch M, Nekljudova V, Mehta K, Loibl S. Fatal events during clinical trials: an evaluation of deaths during breast cancer studies. Breast Cancer 2019; 26:826-834.|
|type||journal paper/review (English)|
|date of publishing||28-06-2019|
|journal title||Breast Cancer (26/6)|